Randomised controlled trial of mesalazine in IBS
Low-grade intestinal inflammation plays a role in the pathophysiology of IBS. We conducted a phase 3, multicentre, tertiary setting, randomized, double-blind, placebo-controlled trial. Patients were randomly assigned to either mesalazine, 800 mg, or placebo, three times daily for 12 weeks.

Related Post